Internal restructuring
Location of affected unit(s)
Switzerland, UK, Ireland, India, Kuala, Malaysia, Mexico and Czech republic
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.1 - Manufacture of basic pharmaceutical products

22,000 jobs
Number of planned job losses
Job loss
700 jobs
Number of planned job creations
Job creation
Announcement Date
25 September 2018
Employment effect (start)
1 October 2018
Foreseen end date
1 January 2022


The Swiss phamaceutical group Novartis has announced a reduction of its global workforce from currently 122,000 employees to less than 100,000 by 2022, with the aim reduce production costs and increase its profitability. In this framework, the group has announced 2,200 job cuts in Switzerland as well as 395 job losses in the UK  with the closure of its plant at Grimsby. In Switzerland, the net job losses over the same period will be 1,750 as the company has also announced the recruitment of 450 employees in its cell and gene therapy activities located at Stein. 

Out of the 2,200 job reductions, 700 will affect its services mainly based in Basel, as the activity will be distributed in service centres around the world: Dublin (Ireland), Hyderabad (India), Kuala Lumpur (Malaysia), Mexico (Mexico) and Prag (Czech republic). The management announces that it has already invited staff representatives and executives in Switzerland to dialogue and consultation. The company will offer its full support to all employees concerned, including the establishment of a job search centre, internal and external reemployment measures, a social plan and an early retirement plan. A previous worldwide restructuring is recorded in the ERM database in 2007 with 2,500 job cuts.



Eurofound (2018), Novartis, Internal restructuring in World, factsheet number 95518, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/95518.